Importantly, our research wants to uncover that PD-L1/TP63 immunostaining may be a preliminary screening for further molecular detection of some DLBCL cases, and targeting PD-L1/TP63 may be an ideal treatment for some patients. The gene discussed is TP63; the disease is diffuse large B-cell lymphoma.